151 related articles for article (PubMed ID: 36534274)
1. Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial.
Bar-Or A; Montalban X; Hu X; Kropshofer H; Kukkaro P; Coello N; Ludwig I; Willi R; Zalesak M; Ramanathan K; Kieseier BC; Häring DA; Bagger M; Fox E
Neurol Ther; 2023 Feb; 12(1):303-317. PubMed ID: 36534274
[TBL] [Abstract][Full Text] [Related]
2. Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
Fox RJ; Cree BAC; de Sèze J; Gold R; Hartung HP; Jeffery D; Kappos L; Montalban X; Weinstock-Guttman B; Singh CM; Altincatal A; Belviso N; Avila RL; Ho PR; Su R; Engle R; Sangurdekar D; de Moor C; Fisher E; Kieseier BC; Rudick RA
Neurology; 2024 May; 102(9):e209357. PubMed ID: 38648580
[TBL] [Abstract][Full Text] [Related]
3. Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal Cohort.
Steffen F; Uphaus T; Ripfel N; Fleischer V; Schraad M; Gonzalez-Escamilla G; Engel S; Groppa S; Zipp F; Bittner S
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36411080
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials.
Ziemssen T; Arnold DL; Alvarez E; Cross AH; Willi R; Li B; Kukkaro P; Kropshofer H; Ramanathan K; Merschhemke M; Kieseier B; Su W; Häring DA; Hauser SL; Kappos L; Kuhle J
Front Immunol; 2022; 13():852563. PubMed ID: 35432382
[TBL] [Abstract][Full Text] [Related]
5. Serum neurofilament light chain correlations in patients with a first clinical demyelinating event in the REFLEX study: a
Kuhle J; Leppert D; Comi G; de Stefano N; Kappos L; Freedman MS; Seitzinger A; Roy S
Ther Adv Neurol Disord; 2024; 17():17562864241239101. PubMed ID: 38560407
[TBL] [Abstract][Full Text] [Related]
6. Implications of extreme serum neurofilament light chain levels for the management of patients with relapsing multiple sclerosis.
Engel S; Protopapa M; Steffen F; Papanastasiou V; Nicolaou C; Protopapas M; Zipp F; Bittner S; Luessi F
Ther Adv Neurol Disord; 2021; 14():17562864211001977. PubMed ID: 33959194
[TBL] [Abstract][Full Text] [Related]
7. Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis.
Rosso M; Gonzalez CT; Healy BC; Saxena S; Paul A; Bjornevik K; Kuhle J; Benkert P; Leppert D; Guttmann C; Bakshi R; Weiner HL; Chitnis T
Ann Clin Transl Neurol; 2020 Jun; 7(6):945-955. PubMed ID: 32452160
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of individual serum neurofilament light chain levels in short-term disease activity in relapsing multiple sclerosis.
Solís-Tarazona L; Raket LL; Cabello-Murgui J; Reddam S; Navarro-Quevedo S; Gil-Perotin S
Front Neurol; 2024; 15():1354431. PubMed ID: 38426169
[TBL] [Abstract][Full Text] [Related]
9. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment.
Højsgaard Chow H; Petersen ER; Olsson A; Hejgaard Laursen J; Bredahl Hansen M; Oturai AB; Soelberg Sørensen P; Bach Søndergaard H; Sellebjerg F
Mult Scler Relat Disord; 2024 Jun; 88():105701. PubMed ID: 38889559
[TBL] [Abstract][Full Text] [Related]
10. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes.
Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852
[TBL] [Abstract][Full Text] [Related]
11. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
[TBL] [Abstract][Full Text] [Related]
12. Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial.
Cutter G; Rudick RA; de Moor C; Singh CM; Fisher E; Koster T; Lublin FD; Wolinsky JS; McFarland H; Jacobson S; Naylor ML
Mult Scler J Exp Transl Clin; 2023; 9(2):20552173231169463. PubMed ID: 37139460
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D supplementation and serum neurofilament light chain in interferon-beta-1b-treated MS patients.
Hänninen K; Jääskeläinen O; Herukka SK; Soilu-Hänninen M
Brain Behav; 2020 Sep; 10(9):e01772. PubMed ID: 32705821
[TBL] [Abstract][Full Text] [Related]
14. Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
Calabresi PA; Arnold DL; Sangurdekar D; Singh CM; Altincatal A; de Moor C; Engle B; Goyal J; Deykin A; Szak S; Kieseier BC; Rudick RA; Plavina T
Mult Scler; 2021 Sep; 27(10):1497-1505. PubMed ID: 33307998
[TBL] [Abstract][Full Text] [Related]
15. High or increasing serum NfL is predictive of impending multiple sclerosis relapses.
Thebault S; Reaume M; Marrie RA; Marriott JJ; Furlan R; Laroni A; Booth RA; Uccelli A; Freedman MS
Mult Scler Relat Disord; 2022 Mar; 59():103535. PubMed ID: 35078125
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
Huppke B; Reinert MC; Hummel-Abmeier H; Stark W; Gärtner J; Huppke P
Neurology; 2023 Nov; 101(19):e1873-e1883. PubMed ID: 37748882
[TBL] [Abstract][Full Text] [Related]
17. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management.
Freedman MS; Gnanapavan S; Booth RA; Calabresi PA; Khalil M; Kuhle J; Lycke J; Olsson T;
EBioMedicine; 2024 Mar; 101():104970. PubMed ID: 38354532
[TBL] [Abstract][Full Text] [Related]
18. Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study.
Johnsson M; Stenberg YT; Farman HH; Blennow K; Zetterberg H; Malmeström C; Sandgren S; Rosenstein I; Lycke J; Axelsson M; Novakova L
Mult Scler; 2024 May; 30(6):664-673. PubMed ID: 38481083
[TBL] [Abstract][Full Text] [Related]
19. Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity-a cohort study.
Hegen H; Berek K; Bsteh G; Auer M; Altmann P; Di Pauli F; Grams A; Milosavljevic D; Ponleitner M; Poskaite P; Schnabl C; Wurth S; Zinganell A; Berger T; Walde J; Deisenhammer F
EBioMedicine; 2023 May; 91():104573. PubMed ID: 37086651
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension.
Hauser SL; Zielman R; Das Gupta A; Xi J; Stoneman D; Karlsson G; Robertson D; Cohen JA; Kappos L
Mult Scler; 2023 Oct; 29(11-12):1452-1464. PubMed ID: 37691530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
